AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03094715 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Best medical care
Description: Best medical treatment will be performed as detailed in established Standard Operating Procedures, following regional guidelines (American Heart Association (AHA), European Stroke Organisation (ESO), Deutsche Schlaganfall-Gesellschaft (DSG), local country, etc.). If applicable, the reason for iv tissue plasminogen activator (tPA) ineligibility has to be documented on the eCRF.
Study NCT04245813 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interdisciplinary educational program
Description: Interdisciplinary educational component based on the Clinical Practice Guide for Heart Failure
Study NCT01156857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGL4001, placebo
Description: PGL4001 10mg once daily (oral tablets) for 3 months followed by a period of 10 days of placebo (oral tablets).
Study NCT01156857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGL4001, progestin
Description: PGL4001 10mg once daily (oral tablets) for 3 months followed by a period of 10 days of progestin Norethisterone acetate 10mg once daily (oral tablets).
Study NCT01302340 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Delta-THC
Description: Active treatment consists of THC in tablet form. Patients receive 0.75 mg THC twice daily during the first three treatment blocks (period A) and 1.5 mg THC twice daily during the latter three treatment blocks (period B). Placebo treatment consists of two tablets daily and is matched to the active treatment for taste, color and size. Study medication will be administered at 10 a.m. and 4 p.m., by the primary caregiver. These time points are chosen because NPS often occur later on the day, when fatigue and external signals build up to the stress and result in NPS. The order of administration of THC and placebo (1:1) will be determined by randomization per block: THC followed by placebo or placebo followed by THC.
Study NCT01302340 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Active treatment consists of THC in tablet form. Patients receive 0.75 mg THC twice daily during the first three treatment blocks (period A) and 1.5 mg THC twice daily during the latter three treatment blocks (period B). Placebo treatment consists of two tablets daily and is matched to the active treatment for taste, color and size. Study medication will be administered at 10 a.m. and 4 p.m., by the primary caregiver. These time points are chosen because NPS often occur later on the day, when fatigue and external signals build up to the stress and result in NPS. The order of administration of THC and placebo (1:1) will be determined by randomization per block: THC followed by placebo or placebo followed by THC.
Study NCT01302340 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Delta-THC
Description: In case either 2 times daily 1 tablet 0,75mg or 2 times daily 1 tablet 1.5mg Delta-THC appeared to be efficacious for a particular patient, this patient can continue the effective dose of delta-THC in an open label extension phase during 6 months.
Study NCT02666079 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LightPath® Imaging System.
Description: Intra-operative use of the LightPath® Imaging System.
Study NCT01442545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-39758979 / MTX
Description: Day 1: MTX: Route=oral use, single dose of participant's weekly MTX dose; Days 3-15: MTX: Route=oral use, single dose of participant's weekly MTX dose and JNJ 39758979: Type=exact, unit=mg, number=300, form=tablet, route=oral use, administered daily.
Study NCT02906644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lorcaserin
Study NCT02906644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine patch
Study NCT03529201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: administered by PCA
Study NCT05268159 — intervention group
Intervention type: OTHER
Intervention: Cognitive assessment
Description: Assessment of unilateral spatial neglect, attention, executive functions and memory
Study NCT04700358 — intervention group
Intervention type: OTHER
Intervention: Blood sampling
Description: Screening: Blood sampling of 15 ml whole blood~B cell isolation: Blood sampling of max. 400 ml whole blood or 6% of the total blood volume (♀ 65 ∓ 10 ml/kg; ♂ 77 ∓ 10 ml/kg)
Study NCT03253887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethanol-lock
Description: This group received daily alcohol 70% (ethanol-lock) received intraluminal ethanol at a volume sufficient to fill the catheter lumen, ranged from 0.1 to 0.3 ml, with the volume being previously established. ELT was maintained for two full hours in each catheter lumen, with the lumen remaining locked during this period. The same procedure was then carried out with the other lumen. Prior to and following ELT, flushing was performed using 5-10 ml of 0.9% saline solution.
Study NCT03529201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Inhalational anesthetic during GA
Study NCT03529201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: painkiller during GA
Study NCT03529201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: muscle relaxant during GA
Study NCT01329640 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug: Paclitaxel; trastuzumab; doxorrubicin; cyclophosphamide
Description: 1. Paclitaxel 100mg/m2 once a week for 8 weeks concomitant to trastuzumab 4mg/kg dose attack after 2mg/kg once a week for 8 weeks followed by;~2. Doxorrubicin 24mg/m2 once a week concomitantly with oral cyclophosphamide 100mg/day (flat dose) concomitantly with trastuzumab 2mg/kg for 9 weeks
Study NCT01312090 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Whole body cryotherapy
Description: Cryotherapy: The whole-cody cryotherapy device (Univers Cryo-Combi;Oy MJG Univers Ab, Helsinki, Finland) consists of 3 chambers set at different temperatures. The first 2 chambers are meant for precooling (-30°Cand-60°C), and the patient remains in these for a very short time. The third chamber temperature reaches -110°C, and the patient remains inside for 3-4 minutes wearing a bathing suit or trunks, acral parts covered.
Study NCT01312090 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: counseling and behavioral therapy for weight loss
Description: Weight loss intervention with Very Low Calory Diet (VLCD, 500-1000 kcal / d + dietary supplements) and group and individual treatment (eating, physical activity counseling and behavioural therapy).
Study NCT02166658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: Cabazitaxel 25 mg/m2 i.v. infusion (infusion time about 1h) on D1 of each 21-day cycle. Continuation of treatment until progression of brain metastases or unacceptable toxicity.
Study NCT03624660 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HR-A
Description: The prostate and proximal seminal vesicles will be treated to 2 cobalt gray equivalent per fraction for 39 fractions for a total of 78 cobalt gray equivalent.~Simultaneous integrated boost to the IPT will be delivered to 2.2 cobalt gray equivalent per fraction for 39 fractions for a total of 85.8 cobalt gray equivalent.~Treatment will be given once a day, approximately 5 treatments per week (Monday- Friday), over 8-9 weeks.
Study NCT00439036 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior Therapy
Description: The Act-ODT intervention will consist of 24 50-minute sessions delivered weekly in the context of a methadone dose reduction program. Sessions will begin during the methadone run-up/stabilization period approximately 4 weeks prior to the onset of dose reduction and will continue through the 20 week detoxification.
Study NCT00439036 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Drug Counseling
Study NCT02501200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-391
Description: Investigational product is prescribed to all of randomized subjects for two times.
Study NCT02906644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo lorcaserin
Study NCT03624660 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HR-B
Description: The prostate, proximal seminal vesicles, and pelvic nodes will be treated to 2 cobalt gray equivalent per fraction for 23 fractions for a total of 46 cobalt gray equivalent.~The prostate and proximal seminal vesicles will be treated to an additional 2 cobalt gray equivalent per fraction for 16 fractions for a total of 32 cobalt gray equivalent.~Electively treat the entire uninvolved seminal vesicle to 2 cobalt gray equivalent per fraction for 39 fractions for a total of 78 cobalt gray equivalent when part of the seminal vesicle is involved with tumor.~Simultaneous integrated boost to the IPT will be delivered to 2.2 cobalt gray equivalent per fraction for 39 fractions for a total of 85.8 cobalt gray equivalent.~Treatment will be given once a day, approximately 5 treatments per week (Monday- Friday), over 8-9 weeks.
Study NCT03322488 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fistulodesis
Description: Fistulodesis comprises the following treatment steps:~* Curettage and/or brushing of the fistula tract~* Mini-excision of the inner (endoanal) fistula opening~* Flushing of fistula tract with acetylcysteine (Concentration: 100mg/ml, max. dosage: 20ml)~* Flushing/ filling of fistula tract with doxycycline (Concentration: 20mg/ml, max. dosage: 10ml)~* Filling the fistula tract with fibrin-glue (Evicel®). The maximum amount of Evicel® injected will be 20 ml of the combined product.~* Surgical closure of inner (endoanal) fistula opening using a Z-suture (Vicryl 3.0)~* Surgical closure of the outer fistula opening using a Z-suture (Vicryl 3.0)~Metronidazole and ciprofloxacin will be used at 500mg two times per day for 10 days after the intervention (baseline).
Study NCT04306874 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ensure Max Protein
Description: Liquid shake with 30 g protein per serving
Study NCT01210365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diurisa®
Description: Furosemide 40 mg + amiloride chloride 10 mg.The patient will swallow onde tablet per day in whole form on an empty stomach with some liquid during 4 weeks.
Study NCT01210365 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lasix ®
Description: One group of patients will receive furosemide 40mg .The patient will swallow the tablet in whole form on an empty stomach with some liquid.
Study NCT05440279 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: digital patient support
Description: Intervention takes place through a regular electronic therapy support in addition to standard care that is defined as follows:~Emails to patients with personalized, automated feedback on their therapy (derived from device data received via modem or data entered by the patient via electronic questionnaire),~1. electronic questionnaires (web-based) on possible problems during therapy and subjective therapy success,~2. possibility to set personal adherence goals every week,~3. links to explanations and videos on therapy and the handling of therapy equipment and accessories,~4. provision of data for the trial center in the event of contact by the patient, as well as for routine therapy monitoring.
Study NCT00873509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone
Description: Buspirone liquid, 2.5 mg in 1 ml, once per day in the evening for the first week of administration and thereafter twice a day 12 hours apart for the entire study
Study NCT00873509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone
Description: Buspirone liquid, 5.0 mg in 1 ml , once per day in the evening for the first week of administration and thereafter twice a day 12 hours apart for the entire study
Study NCT00873509 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo liquid, in 1 ml, once per day in the evening for the first week of administration and thereafter twice a day 12 hours apart for the entire study
Study NCT02501200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atrovastatin and Ezetimibe combination therapy
Description: Investigational products are prescribed to all of radomized subjects for two times.
Study NCT03706300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guaifenesin and Pseudoephedrine Hydrochloride Extended Release Tablets 1200/120 mg
Study NCT01245270 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bilberry capsule first, then control cap
Description: Male subjects aged >40 and \<70 years, with type 2 diabetes controlling their diabetes by diet alone closely matched for adiposity as determined by waist circumference (n=8).~Volunteers will be randomised double blinded into two groups (n=4 per group) and given a single capsule of either 0.47 grams of a bilberry extract (mirtoselect provided by Indena S.p.A (http://www.mirtoselect.info/) or a control capsule. Following a two week wash out period the volunteers will be asked to take a second single capsule of either of 0.47 grams of mirtoselect or a control capsule in a cross over study, the opposite of what they took the first time.
Study NCT01245270 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control capsule first then bilberry cap
Description: Male subjects aged >40 and \<70 years, with type 2 diabetes controlling their diabetes by diet alone closely matched for adiposity as determined by waist circumference (n=8).~Volunteers will be randomised double blinded into two groups (n=4 per group) and given a single capsule of either 0.47 grams of a bilberry extract (mirtoselect provided by Indena S.p.A (http://www.mirtoselect.info/) or a control capsule. Following a two week wash out period the volunteers will be asked to take a second single capsule of either of 0.47 grams of mirtoselect or a control capsule in a cross over study, the opposite of what they took the first time.
Study NCT01321125 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bacterial culture of the prepared skin's areas
Description: Cultures were taken with a scrub-cup of 5cm2 of internal area pressed over the skin previously prepared, then it was added a 3mL of culture broth (C/E neutralizing broth (D/E Neutralizing Broth, DIFCO TM) containing a neutralizing agent and a detergent agent (1% solution tween-80) as washing solution. The skin was scrub with a sterile rubber policeman for 2 minutes, and the procedure was conducted once again. Both aliquots were gathered together in a sterile tube, and a sample of 50mL was spread in a plate containing a neutralizing agar (D/E neutralizing Agar, DIFCO TM) and incubated at 35°C for 72 hrs. After incubation, the colonies were counted.
Study NCT01321125 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preparing skin's areas to be tested
Description: Two antiseptics (2% chlorhexidine gluconate in 70% isopropyl alcohol and 10% sodium hypochlorite) and two controls were tested as skin antiseptics. The intervention consisted of preparing four skin's areas with the antiseptic or the control, two in each arm of the volunteer. These ones were approximately 25cm2 on the forearm for each antiseptic or control. The antiseptic or control were applied in an outward circular motion using a swab that was soaked with the solution. The solution was kept on the skin for 60 seconds before the bacterial culture was conducted. Every volunteer were studied in three separate occasions, alternating the four areas in every subsequent test, so every area was studied with each control or antiseptic.
Study NCT01321125 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antiseptic substantivity
Description: Three antiseptics will be tested: 2% chlorhexidine gluconate in 70% isopropyl alcohol, 10% sodium hypochlorite and 10% povidone-iodine, each one will be applied on the surface of one fingertip each, and will be allow to dry for 60 seconds, then the remaining antiseptic on the skin will be wash out with distilled water. The evaluated zones will be dried with sterile gauze, and then will be covered with sterile gauze for two hours. After this period, each finger will be placed for 30 seconds on an agar plate, which will be inoculated whit an ATCC E. coli. The plate will be incubated at 35ºC for 72 hrs. After incubation, a blinded technician will report the presence or absence of bacterial growth
Study NCT04572607 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: The consumption of avocado honey was analyzed
Description: The subjects of honey group consumed 25 g of honey each day for 4 weeks.
Study NCT03846856 — intervention group
Intervention type: OTHER
Intervention: Biopsy
Description: Biopsy taken during surgical procedure
Study NCT00575003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYT003-QbG10
Description: 6 subcutaneous injections
Study NCT00575003 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CYT003-QbG10
Description: 6 subcutaneous injections
Study NCT00667381 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real-time Ultrasound Guidance (Site-Rite 5 or 6 machine)
Description: Real-time ultrasound guidance will be used to aid in femoral artery cannulation. This will occur with a 7 MHz ultrasound probe covered with a sterile cover.
Study NCT03558503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UGN-102
Description: UGN-102 consists of mitomycin and sterile hydrogel (a proprietary thermally responsive gel) that is used to reconstitute mitomycin before instillation. The reverse thermal properties of UGN-102 allow for local administration of mitomycin as a liquid, with subsequent conversion to a semi-solid gel depot following instillation into the bladder.~The UGN-102 admixture for intravesical instillations contains 75 mg mitomycin in 56 mL admixture (1.33 mg mitomycin per 1 mL).
Study NCT03216499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIF-2alpha Inhibitor PT2385
Description: Given PO
Study NCT03716856 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CAR-BCMA T cells
Description: Single dose of CAR-BCMA T cells will be infused, and classic 3+3 dose escalation will be applied.
Study NCT03706300 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Guaifenesin and Pseudoephedrine Hydrochloride Extended Release Tablets 1200/120 mg
Study NCT01716455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSP-004184
Study NCT01111279 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gpASIT+TM
Description: 1 subcutaneous injection every 7 days, during 29 days.
Study NCT01111279 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gpAST+TM/adjuvant
Description: 1 subcutaneous injection every 7 days, during 29 days
Study NCT01111279 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo solution
Description: 1 subcutaneous injection every 7 days, during 29 days
Study NCT01753401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acthar
Description: Acthar is given by subcutaneous (SC) injection (shot under the skin), at a dose of 40 units daily or 80 units every other day
Study NCT01753401 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo contains the same inactive ingredients as Acthar, and is given by SC injection
Study NCT01753401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo contains the same inactive ingredients as Acthar, and is given by SC injection
Study NCT01753401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroid Drug
Description: The patient's steroid regimen 7.5 to 30 mg/day of prednisone or equivalent, chronic/stable within the 4 weeks prior to screening.
Study NCT01753401 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Steroid Drug
Description: The patient's steroid regimen 7.5 to 30 mg/day of prednisone or equivalent, chronic/stable within the 4 weeks prior to screening.
Study NCT00610389 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: immunotherapy with dendritic cells
Description: We will administer four daily doses (repeated every 24 hours)o dendritic cells in two cycles one month apart. We will administer systemic treatment with PEG-IFN alfa and GM-CSF to potentiate activity.
Study NCT02816463 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ambu AuraGain
Study NCT02816463 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LMA Supreme
Study NCT00545103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD476, MMX™ mesalazine, 1.2g extended release tablet
Description: SPD476 1.2g administered Once Daily (QD)
Study NCT00545103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD476, MMX™ mesalazine, 2.4g extended release tablet
Description: SPD476 2.4g administered Once Daily (QD)
Study NCT00545103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD476, MMX™ mesalazine, 4.8g extended release tablet
Description: SPD476 4.8g administered Once Daily (QD)
Study NCT05333900 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Plant-Based Diet then animal-based diet
Description: Participants started with plant based diet: high in fiber, low in animal products for 7 days, with 14 day washout period between interventions. Following that, participants were switched to animal-based diet: high in animal products, low in fiber for 7 days.
Study NCT05333900 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Animal-based diet then plant-based diet
Description: Participants were started with animal-based diet: high in animal products, low in fiber for 7 days, with 14 days washout period between interventions. Following that, participants were switched to plant-based diet: high in fiber, low in animal products for 7 days